ArticleFrontiers in oncology2026
Initial clinical experience with total Müllerian compartment resection for locally advanced cervical cancer: a single-center preliminary retrospective cohort study and learning-curve analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In this study, we compared the clinical value of embryonic compartment hysterectomy-i.e., total Müllerian compartment resection (TMCR)-with traditional radical hysterectomy for treating locally advanced cervical cancer, and assessed the learning curve associated with this novel technique. Methods: We conducted a retrospective cohort analysis at the Second Affiliated Hospital of Dalian Medical University that comprised 60 women who underwent initial surgical treatment for cervical cancer (FIGO stages IB3 and IIA2) between May 2018 and May 2024. Participants were assigned to an embryonic-compartment hysterectomy group (n=37) and a traditional hysterectomy group (n=23). We collected demographic data, oncologic information, treatment-related complications, and follow-up data. Perioperative outcomes and oncologic results were compared between the groups, and the learning curve for TMCR was analyzed by applying cumulative sum (CUSUM) and best-fit curve analyses based on surgical duration. Results: We noted no significant differences in age, body mass index, tumor stage, pathologic type, surgical duration, or postoperative hospital stay between the two groups (P>0.05). However, the TMCR ("study") group exhibited less intraoperative blood loss, with a median of 100 ml (50-200 ml) compared with 300 ml (110-500 ml) in the traditional group (P<0.05). Postoperative complication rates were similar, with 24.3% in the study group and 17.4% in the traditional group (P>0.05). The overall median follow-up duration was 30 months; however, the traditional group was followed for a median of 41 months compared with 23 months for the study group. All recurrences and deaths occurred in the traditional group. In addition, the median tumor size in the study group was 51 mm (IQR, 45-57.5 mm), compared with 46 mm (IQR, 42-50 mm) in the traditional group (P<0.05). The CUSUM curve peaked after the 12th case, indicating a transition from learning to proficient phases, with significantly reduced surgical times in the proficient phase (P<0.05). Conclusions: TMCR is safe and feasible for locally advanced cervical cancer. We posit that gynecologic oncologists will be able to achieve proficiency after performing 12 cases, with potential advantages in resecting larger tumors. However, further longitudinal studies and larger clinical trials are necessary to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.